Where is TB 161 Sourced From?

Stable Supply of Terbium-161 Ensures Timely Treatment for Our Patients

Terbium-161 (Tb-161) is a next-generation radionuclide used in targeted radioligand therapy, especially for patients with metastatic castration-resistant prostate cancer (mCRPC). The effectiveness of this therapy depends on delivering the dose at precise intervals. At our centre, we maintain a *stable and uninterrupted supply of Tb-161, made possible through our partnership with **Terthera*, the world’s leading supplier of medical-grade Terbium.

Based in the Netherlands, Terthera recently crossed a major production milestone by manufacturing over 200 Ci (7.4 TBq) of Tb-161, confirming its position as a reliable global provider. This milestone was shared on their LinkedIn page:

[https://www.linkedin.com/pulse/terthera-reached-milestone-producing-over-200ci-74tbq-terbium-161-c7wre]

We receive regular shipments of Tb-161 twice a month, which ensures that treatment cycles are never delayed. This reliability is crucial in radioligand therapy, where missing a dose can affect the therapy's efficacy.

For International Patients, we offer priority appointment scheduling to coordinate efficiently with travel timelines and treatment windows. This helps minimize wait times and ensures timely access to therapy upon arrival.

By working closely with Terthera and maintaining internal scheduling discipline, our centre is fully equipped to provide Tb-161 treatment on time, every time. This operational strength translates into better outcomes and peace of mind for patients undergoing one of the most advanced therapies in nuclear medicine.

Also Read